Search results: (10000)
News Frequent Nausea During Chemotherapy Despite Antiemetic Prophylaxis
Current clinical research has focused on vomiting as a primary issue in the occurrence of CINV (chemotherapy-induced nausea and vomiting) and, using recommended antiemetic prophylaxis, this problem has been relatively well managed. However, the incidence and impact of nausea are underreported. We present the results of an observational study that evaluated the incidence of nausea in patients undergoing chemotherapy.
News When to Switch to Second-Line Treatment for Primary Biliary Cholangitis?
In patients with primary biliary cholangitis (PBC), the response to ursodeoxycholic acid (UDCA) treatment is an important prognostic indicator. To identify patients with an insufficient response to this modality who require second-line therapy, the best practice is to assess the biochemical response to UDCA after 12 months of treatment. A validated and easy-to-use tool is the determination of serum alkaline phosphatase (ALP) activity and serum total bilirubin concentration. Although treatment response to UDCA is commonly checked after 12 months, a 6-month check has the same discriminatory value.
News Efficacy of Bruton Tyrosine Kinase Inhibitors After Venetoclax Therapy in Patients with CLL
Targeted therapy has changed the treatment approach for chronic lymphocytic leukemia (CLL), showing higher efficacy and safety compared to standard chemoimmunotherapy. Until recently, an important question remained unanswered: whether the administration of Bruton tyrosine kinase inhibitors (BTKi) after previous therapy with the BCL-2 inhibitor venetoclax provides sufficient clinical effect.
News The safety of dupilumab allows treatment of atopic dermatitis without routine laboratory monitoring
The first comprehensive analysis of laboratory data from 3 clinical trials with dupilumab assessed the incidence of clinically significant changes in hematological or biochemical parameters in patients with moderate to severe atopic dermatitis.
News Perioperative Management of Bleeding in Patients with von Willebrand Disease Using Coagulation Factors
Von Willebrand disease is one of the most common congenital bleeding disorders. It is a heterogeneous group of diseases with varying severity of clinical manifestations. Some patients require pharmacological prevention or treatment of bleeding as part of perioperative care. The administration of concentrates containing coagulation factors is currently the gold standard for certain types of von Willebrand disease.
News Mechanism of Action of Venopharmaceuticals and Their Use in the Treatment of Chronic Venous Insufficiency
Venopharmaceuticals are the cornerstone of conservative treatment for chronic venous insufficiency (CVD). Their mechanism of action is complex and not yet fully understood. They act on both micro - and macrocirculation, influence the tone of the venous wall, and their anti-inflammatory action is also significant.
News Height as an Independent Risk Factor for Varicose Veins
Authors of a study published in the journal Circulation analyzing data from nearly half a million people found another risk factor for the development of varicose veins – a person's height. They further assessed the possible causal role in the development of this pathology.
News Micronized Diosmin and Flavonoid Fraction – What Do They Have in Common?
Micronized diosmin and micronized purified flavonoid fraction are medications from the flavonoid group that are used as venopharmaceuticals/venoprotectives in the treatment of chronic venous insufficiency and hemorrhoidal disease. Both have many common properties, which we discuss in the following text. Their differences will be covered in a follow-up article on this topic.
News Seventy-day Shedding of SARS-CoV-2 in an Immunocompromised Patient with CLL – A Case Study
A team of American and British experts published the case of a 71-year-old woman with chronic lymphocytic leukemia (CLL) and hypogammaglobulinemia who tested positive for SARS-CoV-2. Despite an asymptomatic course of infection, virus shedding was documented for up to 10 weeks, and viral RNA presence was detected for 15 weeks after the initial detection. The longest recorded virus shedding at the time of the article's publication was 20 days after the first positive test result.
News Diabetic Retinopathy: A Blind Diabetic as Proof of Serious Neglect of Prevention
Diabetic retinopathy is the most common cause of blindness in working-age patients in developed countries. Early detection of diabetic retinopathy offers a chance to preserve vision. Therefore, careful screening and timely initiation of treatment are crucial.
News Risk of Thromboembolism in ITP
Among other possible comorbidities in patients with ITP, thromboembolism represents one of the potential issues that require special attention.
News Fatigue and Quality of Life in Patients with Primary Biliary Cholangitis
Fatigue is the most common symptom of primary biliary cholangitis (PBC). Its occurrence significantly impacts the health-related quality of life of patients.
News INTERACTIVE CASE STUDY of a patient with mCRC treated long-term with various modalities
MUDr. Stanislav John, Ph.D.,
Clinic of Oncology and Radiotherapy, Faculty of Medicine, Charles University and University Hospital Hradec Králové
News Systemic Manifestations of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic progressive disease characterized by remodeling of the pulmonary vessels, leading to the development of right-sided heart failure. Aside from the symptoms of right ventricular failure and pulmonary circulation impairment, patients with PAH also exhibit changes in other organ systems.
News Safety of Riociguat in the Treatment of Thromboembolic Pulmonary Hypertension in Common Practice
In March 2021, the final safety results of riociguat in the treatment of thromboembolic pulmonary arterial hypertension in real-world practice were published from the international EXPERT registry, which also included Czech patients. The safety profile of the therapy was consistent with the findings of previous clinical studies.